ISebe leHlabathi

I-CT011 yimveliso ye-GPC3 CAR T-cell ekhethiweyo yonyango lwe-hepatocellular carcinoma (HCC). I-CT011 yafumana imvume ye-IND kwi-NMPA ngo-2019 yokunyanga izigulana ezine-GPC3-positive solid tumor eyayiyeyona mvume yokuqala yaseTshayina yonyango lwe-CAR T-cell nxamnye ne-solid ...Funda ngokugqithisileyo»

Unjingalwazi weyunivesithi yaseRashiya okwiminyaka yakhe yokugqibela engamashumi asixhenxe unesifo esiphambili se-multiple myeloma. Emva kokufumana unyango oluninzi kunye nokufakelwa i-autologous kabini, wafunda ngonyango oluphambili lokulwa nomhlaza i-CAR-T eTshayina, ngoko ke weza eTshayina ukuze afumane i-CAR-T cell...Funda ngokugqithisileyo»

Ngomhla wama-20 kuJulayi, iSicelo esitsha seDrug (NDA) se-pCAR-19B esaphuhliswa ngokuzimeleyo yiPrecision Biology samkelwa ngokusesikweni yi-China National Medical Products Administration (NMPA). Le mveliso yimveliso yokuqala ye-CAR-T ye-leukemia yabantwana e-China, esetyenziselwa ukunyanga izigulana ezineminyaka emi-3 ukuya kwengama-21 ubudala ...Funda ngokugqithisileyo»

I-satricabtagene autoleucel (Satri-cel, CT041) yimveliso ye-CAR T-cell ekhethiweyo xa ithelekiswa neproteni yeClaudin18.2 enokuba yeyokuqala kwihlabathi liphela. I-Satri-cel ijolise kwiClaudin18.2 solid tumors egxile kakhulu kumhlaza wesisu/umhlaza we-gastroesophageal junction...Funda ngokugqithisileyo»

Ngomhla wesi-6 kweyoMsintsi, ngo-2021, i-JW Therapeutics ibhengeze ukuba i-National Medical Products Administration (NMPA) yaseTshayina ivumile i-New Drug Application (NDA) ye-anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (relma-cel) ...Funda ngokugqithisileyo»

I-Equecabtagene autoleucel (eque-cel), unyango lwe-T-cell oluvela kubantu oluvela kwi-B-cell maturation antigen-targeting chimeric antigen receptor (CAR), lubonakalise amandla okunyanga i-relapse okanye i-refractory multiple myeloma (R/RMM). Ngomhla wama-30 kuJuni, ngo-2023, i-National Medical Products Admi...Funda ngokugqithisileyo»

Ngomhla we-11 kweyeDwarha ngo-2024, i-National Medical Product Administration (NMPA) yaseTshayina ivumile isicelo se-Investigational New Drug (IND) se-Inaticabtagene Autoleucel (CNCT19 Injection), unyango lweeseli ze-antigen receptor (CAR)-T ezijoliswe kwi-CD19, ukunyanga i-Immune thrombocytopenia ...Funda ngokugqithisileyo»

Ngomhla woku-1 kweyoKwindla, ngowama-2024, i-China National Medical Products Administration (NMPA) yavuma ukuqaliswa kwemveliso yeseli ye-CAR-T iZevorcabtagene AutoLeucel (Zevor-cel, CT053) kunyango lwabantu abadala abane-myeloma ephinde yabuyela kwisimo sayo okanye enganyangekiyo abaye baqhubeka emva kweendlela ezintathu zonyango (...Funda ngokugqithisileyo»